Abstract
The oil of black seed (Nigella sativa) has been used as a folk medicine to treat a number of physiological disorders such as epilepsy, gastric problems, allergic conditions and various hepato-biliary ailments. Despite being unaware of the underlying phenomena for the cure of these diseases, people especially in the Mediterranean region have been using this ancient herb since ages. Researches in the 20th century conducted with the aim of tracking molecular pathways of anti-oxidant and anti-inflammatory mechanisms disclosed a great deal of information pertaining to the structural-activity relationships. Rigorous studies revealed that the major active constituent of Nigella sativa oil (NSO) is Thymoquinone (THQ) which exerts the majority of pharmacological actions observed by the essential oil. Since then, a large number of investigator groups have identified numerous molecular pathways of almost all major diseases which can be cured by THQ. Being a phytochemical, THQ has a high lipophilicity which makes it a poorly soluble agent in aqueous fluids restricting its systemic bioavailability. Also, THQ is highly light and heat-sensitive which further complicates its successful formulation for drug delivery. This review thus offers an insight to adequately comprehend the large number of pharmacological actions along with general mechanisms and major molecular targets pertaining to THQ. Additionally, a section dealing with the application of nanotechnological approaches to appropriately deliver the drug to its intended site of action has been elaborated.
Keywords: Anti-cancer, molecular targets, nanoparticles, nanotechnology, thymoquinone, naphthoquinones, formulability, mitochondrial function, scavenging, tyrosine residues
Current Bioactive Compounds
Title:Thymoquinone: Major Molecular Targets, Prominent Pharmacological Actions and Drug Delivery Concerns
Volume: 8 Issue: 4
Author(s): Anjali Singh, Iqbal Ahmad, Sohail Akhter, Mohammad Zaki Ahmad, Zeenat Iqbal and Farhan J. Ahmad
Affiliation:
Keywords: Anti-cancer, molecular targets, nanoparticles, nanotechnology, thymoquinone, naphthoquinones, formulability, mitochondrial function, scavenging, tyrosine residues
Abstract: The oil of black seed (Nigella sativa) has been used as a folk medicine to treat a number of physiological disorders such as epilepsy, gastric problems, allergic conditions and various hepato-biliary ailments. Despite being unaware of the underlying phenomena for the cure of these diseases, people especially in the Mediterranean region have been using this ancient herb since ages. Researches in the 20th century conducted with the aim of tracking molecular pathways of anti-oxidant and anti-inflammatory mechanisms disclosed a great deal of information pertaining to the structural-activity relationships. Rigorous studies revealed that the major active constituent of Nigella sativa oil (NSO) is Thymoquinone (THQ) which exerts the majority of pharmacological actions observed by the essential oil. Since then, a large number of investigator groups have identified numerous molecular pathways of almost all major diseases which can be cured by THQ. Being a phytochemical, THQ has a high lipophilicity which makes it a poorly soluble agent in aqueous fluids restricting its systemic bioavailability. Also, THQ is highly light and heat-sensitive which further complicates its successful formulation for drug delivery. This review thus offers an insight to adequately comprehend the large number of pharmacological actions along with general mechanisms and major molecular targets pertaining to THQ. Additionally, a section dealing with the application of nanotechnological approaches to appropriately deliver the drug to its intended site of action has been elaborated.
Export Options
About this article
Cite this article as:
Singh Anjali, Ahmad Iqbal, Akhter Sohail, Zaki Ahmad Mohammad, Iqbal Zeenat and J. Ahmad Farhan, Thymoquinone: Major Molecular Targets, Prominent Pharmacological Actions and Drug Delivery Concerns, Current Bioactive Compounds 2012; 8 (4) . https://dx.doi.org/10.2174/1573407211208040003
DOI https://dx.doi.org/10.2174/1573407211208040003 |
Print ISSN 1573-4072 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6646 |
Call for Papers in Thematic Issues
Antioxidants: Unveiling their Power in Health and Disease
Antioxidants have captured significant interest for decades due to their potential role in preventing chronic diseases. These molecules combat free radicals and unstable molecules that damage cells and contribute to the development of conditions like metabolic diseases, heart disease, cancer, and neurodegenerative diseases. This thematic issue will explore the cutting-edge ...read more
Bioactive Compounds: An Ideal Source for Drug Discovery, Design, Development and Target Identification
The Special Issue "Bioactive Compounds: Discovery, Design, Development, and Target Identification" aims to bring together innovative research and critical reviews on bioactive molecules that show therapeutic potential across diverse diseases. Discovery of novel bioactive compounds will focus on uncovering new molecules from natural or synthetic sources, expanding the library of ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Perspective on mTOR-dependent Protection in Status Epilepticus
Current Neuropharmacology Neonatal Brain Hemorrhage (NBH) of Prematurity: Translational Mechanisms of the Vascular-Neural Network
Current Medicinal Chemistry Regulation of Medical Devices and their Clinical Trials Studies in the USA: An Update
Recent Innovations in Chemical Engineering Winning a Won Game: Caffeine Panacea for Obesity Syndemic
Current Neuropharmacology Applications of Artificial Neural Networks in Medical Science
Current Clinical Pharmacology Efficacy, Duration and Timing of Withdrawal of Prophylactic Treatment with Antiepileptic Drugs in Neurosurgical Conditions
Current Pharmaceutical Design Synthesis and Anticonvulsant Activity of Some Novel Semicarbazone Containing Benzoxazole: Pharmacophore Model Study
Current Bioactive Compounds Synthesis and Anticonvulsant activity of Fluorinated Cyclic Enaminones
Letters in Drug Design & Discovery “Epileptic Encephalopathy” of Infancy and Childhood: Electro-Clinical Pictures and Recent Understandings
Current Neuropharmacology Simple and Fast Gas-chromatography Mass Spectrometry Assay to Assess Delta 9-Tetrahydrocannabinol and Cannabidiol in Dogs Treated with Medical Cannabis for Canine Epilepsy
Current Pharmaceutical Biotechnology Design, Characterization and Evaluation of Anti-epileptic Activity of Nanoprecipitating Preconcentrate of Carbamazepine
Drug Delivery Letters Mitochondrial Respiratory Complex I: Structure, Function and Implication in Human Diseases
Current Medicinal Chemistry Applications and Synthesis of the Antiepileptic Drug Oxcarbazepine and Related Structures
Current Organic Chemistry Insights into the Cellular Interactions and Molecular Mechanisms of Ketogenic Diet for Comprehensive Management of Epilepsy
Current Neuropharmacology Structure-to-function Relationship of Carbohydrates in the Mechanism of Lysosomal Storage Disorders (LSDs)
Current Organic Chemistry Neuropeptides and Other Chemical Mediators, and the Role of Anti-inflammatory Drugs in Primary Headaches
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry Which Dose of Folic Acid Should Pregnant Diabetic Women Receive?
Recent Patents on Endocrine, Metabolic & Immune Drug Discovery (Discontinued) Small Peptide and Protein-based Molecular Probes for Imaging Neurological Diseases
Current Protein & Peptide Science Meet Our Editorial Board Member
Current Signal Transduction Therapy Lack of Data on Depression-like States and Antidepressant Pharmacotherapy in Patients with Epilepsy: Randomised Controlled Trials are Badly Needed
Current Pharmaceutical Design